BrainsWay to Report Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights on March 23, 2020

Image

PATTERSON, N.J., March 11, 2020 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights on March 23, 2020.

The Company will host a conference call at 8:30 AM Eastern Time to review the financial results and operational highlights.

To participate in the conference call, please dial one of the following numbers 10 minutes prior to the start of the call: United States: +1 631-510-7495; International: +44 (0) 2071 928000; and Israel: +972-3 721 7998. The access code for the call is: 7074659.

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/financial-calendar . Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological and addiction disorders.